Dr. Mark Kris, MD

• Medical Oncology

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• New York Hospital

  Residency Hospital, 1980

• Memorial Sloan-kettering Cancer Center

  Fellowship Hospital, 1980

• New York Hospital

  Internship Hospital, 1978

• Weill Cornell Medical College

  Medical School, 1977

• Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboringBRAFmutations in the Lung Cancer Mutation Consortium, 2014-10-01

• The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials, 2016-10-17

• Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes, 2016-01-21

• Molecular Epidemiology ofEGFRandKRASMutations in 3026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-relatedKRAS-mutant Cancers, 2012-09-26

• AcquiredBRAFrearrangements induce secondary resistance to EGFR therapy inEGFR-mutated lung cancers, 2019-03-01

• HER2amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation, 2012-09-05

• Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated withKRASmutation, 2015-11-23

• A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies, 2010-02-18

• Characteristics and outcomes of patients with metastaticKRASmutant lung adenocarcinomas: The Lung Cancer Mutation Consortium experience., 2019-02-05

• AcquiredALKandRETGene Fusions as Mechanisms of Resistance to Osimertinib inEGFR-Mutant Lung Cancers, 2018-09-04

• Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma withEGFRexon 20 insertions, 2021-03-08

• A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development, 2010-06-09

• Prognostic impact ofKRASmutation subtypes in 677 patients with metastatic lung adenocarcinomas, 2015-06-18

• Targeting Aurora B Kinase Prevents and Overcomes Resistance to EGFR Inhibitors in Lung Cancer by Enhancing BIM- and PUMA-mediated Apoptosis, 2021-08-12

• Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci, 2011-08-03

• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay, 2011-01-19

• Brief Report: Molecular characterization of peritoneal mesotheliomas, 2021-10-11

• Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas, 2017-03-28

• Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C Mutant Non-Small Cell Lung Cancer, 2021-02-08

• Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab, 2020-04-30

• Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling, 2011-07-06

• A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically-resected stage I-IIIA non-small cell lung cancers, 2014-06-20

• Pathologic assessment after neoadjuvant chemotherapy for non-small cell lung cancer: Importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma, 2018-11-29

• Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas, 2009-10-27

• The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study, 2021-07-28

• Phase II Study of Docetaxel and Vinorelbine as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancers, 2013-08-22

• Characteristics of Lung Cancers HarboringNRASMutations, 2013-03-20

• Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients withEGFR-Mutant Lung Cancers., 2018-07-25

• A Phase 2 Single Arm Trial of Cabozantinib in Patients with AdvancedRET-Rearranged Lung Cancers, 2016-11-04

• Toxicity of initial chemotherapy in older patients with lung cancers, 2012-10-10

• KRAS Mutation is a Significant Prognostic Factor in Early Stage Lung Adenocarcinoma, 2016-08-26

• High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden, 2019-04-26

• Brief report: Combination of Osimertinib and Dacomitinib to mitigate primary and acquired resistance inEGFR-mutant lung adenocarcinomas, 2023-04-14

• Driver Mutations Determine Survival in Smokers and Never Smokers with Stage IIIB/IV Lung Adenocarcinomas, 2012-05-17

• A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer, 2011-05-26

• Brief Report: Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas, 2019-12-28

• Comprehensive Long-Term Care of Lung Cancer Patients: Development of a Novel Thoracic Survivorship Program, 2014-07-31

• BRIEF REPORT: SMALL CELL LUNG CANCERS IN PATIENTS WHO NEVER SMOKED CIGARETTES, 2014-07-30

• Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib, 2011-11-17

• MAP2K1 (MEK1)mutations define a distinct subset of lung adenocarcinoma associated with smoking, 2014-10-28

• Outcomes of chemotherapies and HER2 directed therapies in advancedHER2-mutant lung cancers, 2016-05-31

• A Phase I Trial of SJG-136 (NSC#694501) in Advanced Solid Tumors, 2009-08-12

• Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack ofEGFR/KRAS and presence ofPIK3CA/AKT1mutations, 2012-01-06

• Allele-specific role of ERBB2 in the oncogenic function ofEGFRL861Q inEGFR-mutant lung cancers, 2020-10-07

• Association ofKRASandEGFRMutations with Survival in Patients with Advanced Lung Adenocarcinomas, 2012-07-18

• Immunophenotype and Response to Immunotherapy ofRET-Rearranged Lung Cancers, 2019-05-16

• Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer, 2018-05-22

• Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients withRET-Rearranged Lung Cancers, 2018-07-11

• Pathologic response after neoadjuvant chemotherapy in resectable non-small cell lung cancers: proposal for the use of "major pathologic response” as a surrogate endpoint, 2016-01-23

• KRASMutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib, 2005-01-25

• MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven byROS1Fusions, 2020-03-02

• A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer, 2015-12-16

• A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers, 2020-01-09

• Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial, 2015-11-04

• Frequency and Distinctive Spectrum ofKRASMutations in Never Smokers with Lung Adenocarcinoma, 2008-09-15

• EGFRExon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics, 2013-01-31

• Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas, 2011-09-03

• Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance., 2018-03-12

• Trial of a 5-Day Dosing Regimen of Temozolomide in Patients with Relapsed Small Cell Lung Cancers with Assessment of Methylguanine-DNA Methyltransferase, 2014-08-17

• METexon 14-altered lung cancers and MET inhibitor resistance, 2020-11-10

• Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers, 2016-01-05

• Core Needle Lung Biopsy Specimens: Adequacy forEGFRandKRASMutational Analysis, 2013-05-27

• Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large cell carcinoma, 2012-11-30

• Outcomes Following Neoadjuvant or Adjuvant Chemotherapy for cT2-4N0-1 Non-Small Cell Lung Cancer: A Propensity-Matched Analysis, 2018-10-10

• Efficacy and Safety of Bevacizumab in Active Brain Metastases from Non-Small Cell Lung Cancer, 2010-05-04

• HER2Mutations in Lung Adenocarcinomas: A Report from the Lung Cancer Mutation Consortium, 2017-07-25

• Effects of co-occurring genomic alterations on outcomes in patients withKRAS-mutant non-small cell lung cancer, 2017-10-31

• WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis, 2009-07-02

• EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib, 2015-08-18

• Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation, 2010-12-06

• Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer, 2022-07-01

• ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy, 2023-09-19

• Maintained sensitivity to EGFR tyrosine kinase inhibitors inEGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib, 2011-08-10

• Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations, 2013-07-30

• Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab, 2013-06-28

• Next generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases, 2015-04-30

• A Phase 2 Study of Weekly Albumin-Bound Paclitaxel (Abraxane®) Given as a Two-Hour Infusion, 2011-04-03

• Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable non-squamous non-small cell lung cancers, 2014-10-02

• HER2amplification andHER2mutation are distinct molecular targets in lung cancers, 2015-12-24

• Phase II Study of a Non-platinum-containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab (PPB) as Initial Therapy for Patients with Advanced Lung Adenocarcinomas, 2016-03-08

• EGFRExon 19 Insertions: A New Family of SensitizingEGFRMutations in Lung Adenocarcinoma, 2011-12-21

• Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation inFGFR4, 2007-05-09

• ConcurrentRB1andTP53alterations define a subset ofEGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes, 2019-06-19

• SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer, 2018-11-16

• Features of tumor-microenvironment images predict targeted therapy survival benefit in patients withEGFR-mutant lung cancer, 2023-01-17

• EGFRmutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib, 2011-11-21

• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI therapy in 155 patients withEGFRmutant Lung Cancers, 2013-03-07

• Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium experience, 2015-04-21

• Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers, 2021-10-08

• HER2-mediated internalization of cytotoxic agents inERBB2amplified or mutant lung cancers, 2020-03-25

• Activation of KRAS mediates resistance to targeted therapy in MET exon 14 mutant non-small cell lung cancer, 2018-10-23

• Impact of concurrentPIK3CAmutations on response to EGFR tyrosine kinase inhibition inEGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas, 2016-02-07

• Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy, 2017-07-17

• Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC, 2018-07-10

• Response to Erlotinib in Patients withEGFRMutant Advanced Non-Small Cell Lung Cancers with a Squamous or Squamous-like Component, 2012-08-14

• Reflex testing of resected stage I-III lung adenocarcinomas for EGFR and KRAS mutation, report on initial experience and clinical utility at a single center, 2010-10-08

• Beyond steroids: immunosuppressants in steroid-refractory/resistant immune related adverse events, 2021-07-12

• Erlotinib at a dose of 25 mg daily for non-small-cell lung cancers withEGFRmutations, 2010-06-10

• Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report, 2010-01-12

• Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in "driver-negative” lung adenocarcinomas, 2015-01-07

• A phase 1/2 trial of ruxolitinib and erlotinib in patients withEGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib, 2016-09-06

• Deep Learning of Cell Spatial Organizations Identifies Clinically Relevant Insights in Tissue Images, 2023-07-04

• Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies, 2017-03-23

• Safety and pharmacokinetic trial of docetaxel plus anAstragalus-based herbal formula for non-small cell lung cancer patients, 2009-05-07

• Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers, 2019-05-16

• Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC, 2020-02-11

• HER2insertion YVMA mutant lung cancer: long natural history and response to afatinib, 2015-10-29

• MET IHC is a Poor Screen forMETAmplification orMETexon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium, 2019-06-20

• Frequency ofEGFRandKRASMutations in Lung Adenocarcinomas in African-Americans, 2012-04-16

• Twice Weekly Pulse and Daily Continuous Dose Erlotinib as Initial Treatment for Patients withEGFR-Mutant Lung Cancers and Brain Metastases, 2017-09-21

• Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance Pathologist Evaluation of MET Protein Expression, 2019-08-27

• Frequency and Outcomes of Brain Metastases in Patients WithHER2-Mutant Lung Cancers, 2019-08-30

• Targeting S100A9-ALDH1A1-retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer, 2022-04-01

• Evolution of systemic therapy for stages I-III non-metastatic non-small cell lung cancer, 2021-04-28

• Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer, 2014-05-06

• The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2), 2017-12-07

• Response to ERBB3-Directed Targeted Therapy inNRG1-Rearranged Cancers, 2018-04-02

• Response to Selective RET Inhibition With LOXO-292 in a Patient WithRETFusion-Positive Lung Cancer With Leptomeningeal Metastases, 2019-06-03

• Deep learning to estimate RECIST in patients with NSCLC treated with PD-1 blockade, 2020-09-21

• Phase I trial of the TNF-a inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas, 2022-10-15

• Identification ofKIF5B-RETandGOPC-ROS1fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions, 2012-10-10

• DNA Damage and Repair Capacity in Lung Cancer Patients: Prediction of Multiple Primary Tumors, 2008-07-20

• Afatinib in patients with metastatic or recurrentHER2-mutant lung cancers: a retrospective international multicenter study, 2019-01-24

• Adrenal Metastasectomy in the Presence and Absence of Extra-Adrenal Metastatic Disease, 2020-09-06

• Complete Pathological Response to Crizotinib in a Patient withALK-rearranged Lung Adenocarcinoma, 2019-10-13

• A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer, 2016-04-26

• Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial, 2022-09-12

• Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer, 2020-01-07

• The Role of Race in Oncogenic Driver Prevalence and Outcomes in Lung Adenocarcinoma: Results from the Lung Cancer Mutation Consortium (LCMC), 2015-12-22

• Prevalence, clinicopathologic associations and molecular spectrum ofERBB2(HER2) tyrosine kinase mutations in lung adenocarcinomas, 2012-07-03

• Serpins Promote Cancer Cell Survival and Vascular Cooption in Brain Metastasis, 2014-02-27

• Response to Cabozantinib in Patients withRETFusion-Positive Lung Adenocarcinomas, 2013-03-26